Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents
| dc.contributor.author | Alyassin, Yasmine | |
| dc.contributor.author | Sayed, Elshaimaa G. | |
| dc.contributor.author | Mehta, Prina | |
| dc.contributor.author | Ruparelia, Ketan | |
| dc.contributor.author | Arshad, Muhammad S. | |
| dc.contributor.author | Rasekh, Manoochehr | |
| dc.contributor.author | Shepherd, Jennifer | |
| dc.date.accessioned | 2025-10-29T11:29:24Z | |
| dc.date.issued | 2020 | |
| dc.department | Gebze Teknik Üniversitesi | |
| dc.description.abstract | Recently, remarkable efforts have focused on research towards enhancing and delivering efficacious and advanced therapeutic agents. Even though this involves significant challenges, innovative techniques and materials have been explored to overcome these. The advantageous properties of mesoporous silica nanoparticles (MSNs), such as unique morphologies and geometries, makes then favorable for use for various drug delivery targeting purposes, particularly in cancer therapy. As we discuss here, MSNs have been utilized over the past few decades to improve the efficiency of anticancer drugs by enhancing their solubility to render them suitable for application, reducing adverse effects, and improving their anticancer cytotoxic efficiency. | |
| dc.description.sponsorship | Council for At-Risk Academics (CARA) | |
| dc.description.sponsorship | Egyptian Culture Centre | |
| dc.description.sponsorship | Educational Bureau in London | |
| dc.description.sponsorship | The authors would like to thank the Council for At-Risk Academics (CARA) and the Egyptian Culture Centre and the Educational Bureau in London for supporting this work. | |
| dc.identifier.doi | 10.1016/j.drudis.2020.06.006 | |
| dc.identifier.endpage | 1520 | |
| dc.identifier.issn | 1359-6446 | |
| dc.identifier.issn | 1878-5832 | |
| dc.identifier.issue | 8 | |
| dc.identifier.orcid | 0000-0002-1284-8880 | |
| dc.identifier.orcid | 0000-0002-3790-0323 | |
| dc.identifier.orcid | 0000-0003-0207-2246 | |
| dc.identifier.orcid | 0000-0001-7620-9984 | |
| dc.identifier.pmid | 32561300 | |
| dc.identifier.scopus | 2-s2.0-85087213251 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.startpage | 1513 | |
| dc.identifier.uri | https://doi.org/10.1016/j.drudis.2020.06.006 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14854/11082 | |
| dc.identifier.volume | 25 | |
| dc.identifier.wos | WOS:000564772600022 | |
| dc.identifier.wosquality | Q1 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Elsevier Sci Ltd | |
| dc.relation.ispartof | Drug Discovery Today | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.snmz | KA_WOS_20251020 | |
| dc.subject | Co-Delivery | |
| dc.subject | Controlled-Release | |
| dc.subject | In-Vitro | |
| dc.subject | Cancer | |
| dc.subject | Therapy | |
| dc.subject | Systems | |
| dc.subject | Doxorubicin | |
| dc.subject | Paclitaxel | |
| dc.subject | Nanotechnology | |
| dc.subject | Nanocarriers | |
| dc.title | Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents | |
| dc.type | Review Article |








